<DOC>
	<DOCNO>NCT02997748</DOCNO>
	<brief_summary>Acute kidney injury ( AKI ) well-recognized complication cardiac surgery cardiopulmonary bypass ( CPB ) . The aim study reduce incidence AKI implement remote ischemic precondition evaluate dose-response relationship use biomarkers urinary [ TIMP-2 ] * [ IGFBP7 ] high risk patient undergoing cardiac surgery .</brief_summary>
	<brief_title>Remote Ischemic Preconditioning After Cardiac Surgery</brief_title>
	<detailed_description>Acute kidney injury ( AKI ) complicate 7-19 % cardiac surgical procedure . The investigator recently find remote ischemic preconditioning ( RIPC ) use transient external compression upper arm prior cardiac surgery effective reduce occurrence AKI ( 37.5 % compare 52.5 % sham ; absolute risk reduction ( ARR ) ,15 % ; 95 % CI , 2.56 % 27.44 % ; P=0.02 ) . Fewer patient treat RIPC receive renal replacement therapy ( RRT ) ( 5.8 % versus 15.8 % ; ARR , 10 % ; 95 % CI , 2.25 % 17.75 % ; P=0.01 ) . Moreover , investigator find effectiveness intervention strongly associate release cell-cycle arrest biomarkers urine . Patients urinary tissue inhibitor metalloproteinases-2 insulin-like growth factor-binding protein 7 ( [ TIMP-2 ] • [ IGFBP7 ] ) ≥ 0.5 ( ng/ml ) ( ng/ml ) /1000 surgery significantly reduce rate AKI compare patient low urinary [ TIMP-2 ] • [ IGFBP7 ] concentration ( relative risk ( RR ) , 67 % ; 95 % CI , 53 % 83 % , P &lt; 0.001 ) whereas biomarker concentration surgery predict AKI previously show . This effect make sense cell-cycle arrest think part protective mechanism endothelial cell use exposed stress . Stimulating response RIPC reduce AKI . Importantly , 56 % patient treat RIPC achieve increase urine [ TIMP-2 ] • [ IGFBP7 ] ≥ 0.5 , group intervention effective—patients achieve level show benefit . Our goal eventually design conduct Bayesian 2-stage adaptive design sequence trial evaluate effectiveness RIPC prevent AKI patient undergo cardiac surgery . The dimension dose include duration , intensity number cycle . However , trial design need answer 4 question : . Do baseline urinary [ TIMP-2 ] • [ IGFBP7 ] level predict AKI ( enrichment ) ? ii . Do [ TIMP-2 ] • [ IGFBP7 ] change elicit RIPC predict protection ( RIPC efficacy measure ) ? iii . Is dose-response relationship RIPC `` dose '' [ TIMP-2 ] • [ IGFBP7 ] ? iv . Is dose-escalation RIPC protocol dos increase non-responders , feasible safe within anesthesia workflow cardiac surgery case ( practical ) ?</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<criteria>Patients schedule undergo cardiac surgery cardiopulmonary bypass Cleveland Clinic Score &gt; =6 Acute myocardial infarction 7 day surgery Age &lt; 18 year Offpump cardiac surgery Preexisting AKI Chronic kidney disease ( GFR &lt; 30 ml/min ) Kidney transplantation within last 12 month Peripheral arterial occlusive disease Pregnancy Hepatorenal syndrome Sulfonamide thiazide medication within last 7 day Participation another interventional trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>acute kidney injury</keyword>
	<keyword>cardiac surgery</keyword>
	<keyword>Remote ischemic preconditioning</keyword>
	<keyword>[ TIMP-2 ] * [ IGFBP7 ]</keyword>
</DOC>